Loading…
A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study
Background Tetracycline‐containing triple therapy has been suggested as an alternative first‐line therapy for H. pylori infection. Aim To evaluate the effect of two dosages of doxycycline (DOX) associated with amoxicillin and esomeprazole with and without bismuth subcitrate as first‐line treatment o...
Saved in:
Published in: | Helicobacter (Cambridge, Mass.) Mass.), 2015-10, Vol.20 (5), p.390-396 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
Tetracycline‐containing triple therapy has been suggested as an alternative first‐line therapy for H. pylori infection.
Aim
To evaluate the effect of two dosages of doxycycline (DOX) associated with amoxicillin and esomeprazole with and without bismuth subcitrate as first‐line treatment of H. pylori infection.
Methods
Helicobacter pylori‐positive patients underwent a 10‐day therapy randomized into four groups: Group A received esomeprazole, amoxicillin, and DOX‐100 mg b.i.d. (EAD‐100), Group B a quadruple therapy with esomeprazole, amoxicillin, DOX‐100 mg b.i.d. and bismuth subcitrate (EADB‐100), Group C a triple therapy with esomeprazole, amoxicillin, and DOX‐200 mg b.i.d. (EAD‐200) and Group D a quadruple therapy with esomeprazole, amoxicillin, DOX‐200 mg b.i.d., and bismuth subcitrate (EADB‐200). Success was accessed by 13C urea breath test 2 months after the end of treatment. The number of patients to be recruited for each group had to be at least 50 subjects. Treatment success of 80% or less was considered unacceptable. Stopping rules therefore were anytime six failures had occurred.
Results
In the EAD‐100 group and in EAD‐200 group, the recruitment was stopped at the 14th and 15th patient, respectively. Fifty‐two patients entered in the EADB‐100 group and 51 in the EADB‐200 group. Intention to treat eradication was in EADB‐100 group 46/52 (88.5%, 95% CI 76.6–95.6); in the EADB‐200 group 47/51 (92.1%, 95% CI: 81.1–97.8) (n.s.). Side effects were absent.
Conclusion
The adjunction of bismuth subcitrate to a triple therapy that includes esomeprazole, amoxicillin, and DOX in patients who are treated for the first time for the H. pylori infection potentiates the therapeutic effect. This regimen, however, deserves to be optimized in terms of duration and dose of DOX. |
---|---|
ISSN: | 1083-4389 1523-5378 |
DOI: | 10.1111/hel.12209 |